Mecasermin

Evidence Level: L5 Predicted Indications: 51

Quick Overview

Item Value
Drug Name Mecasermin
DrugBank ID DB01277
Brand Names (EU) Increlex
Evidence Level L5
Predicted Indications 51
Top Prediction Score 99.59%

Approved Indication (EMA)

For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD). Severe primary IGFD is defined by: height standard deviation score ? -3.0 and; basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and; growth hormone (GH) sufficiency; exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 monosomy X 99.59% DL
2 Wolman disease with hypolipoproteinemia and acanthocytosis 99.09% DL
3 growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant 99.06% DL
4 esophageal varices without bleeding 99.03% DL
5 esophageal varices with bleeding 99.03% DL
6 autosomal ichthyosis syndrome with fatal disease course 98.67% DL
7 Gaucher disease 98.48% DL
8 varicose disease 98.27% DL
9 congenital pulmonary lymphangiectasia 98.25% DL
10 cholesteryl ester storage disease 98.21% DL
11 benign neoplasm of adrenal gland 98.10% DL
12 16q24.1 microdeletion syndrome 97.93% DL
13 primary interstitial lung disease specific to childhood 97.82% DL
14 isolated pulmonary capillaritis 97.73% DL
15 familial apolipoprotein C-II deficiency 97.38% DL
16 Wolman disease 97.21% DL
17 Steel syndrome 97.17% DL
18 reticular dysgenesis 97.12% DL
19 lysosomal acid lipase deficiency 97.03% DL
20 Hurler syndrome 97.00% DL

Showing top 20 of 51 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.